Cellares, an Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, launched Cell Q, its first automated quality control (QC) workcell for cell therapy manufacturing. Cell Q aims to address the manual, labor-intensive, low-throughput, and expensive nature of cell therapy QC. Exclusive to Cellares’ industry-first IDMO Smart Factories, Cell Q is designed to offer a substantial improvement in throughput, cost, and reproducibility compared to existing manual QC methods.
 
As Cellares Cell Shuttles have addressed upstream bottlenecks in cell therapy manufacturing, Cell Q resolves the downstream QC capacity challenges, according to the company. Cell Q is engineered to automate the vast majority of cell therapy QC assays for up to 6,000 batches per year. To accelerate analytical method transfer and shorten the time to clinical readout for new IDMO clients, Cell Q includes a pre-qualified set of the most common assays. Each Cell Q utilizes a modular platform that can be expanded with new instruments providing the flexibility to meet various client needs. 
 
Cellares offers capacity for upstream cell therapy manufacturing as well as downstream QC via its South San Francisco Center of Excellence and Smart Factory in Bridgewater, NJ. Additional Smart Factories will be coming soon to the EU and Japan.
 
“Cell Q™ was designed to match the throughput of our Cell Shuttle™ platform. This enables the Cellares IDMO to offer a real end-to-end solution for our customers, providing 10 times higher capacity and up to 50% lower batch price,” said Fabian Gerlinghaus, CEO of Cellares. “Our proprietary platform technologies support our mission of becoming the de facto standard for cell therapy manufacturing, accelerating access for patients, and meeting the total patient demand for cell therapies globally.”